Pfizer is a research-based biopharmaceutical company. The company is engaged in discovering, developing, manufacturing and distributing of healthcare products, including medicines and vaccines. The company manages its commercial operations through three businesses: Pfizer Biopharmaceuticals Group, which includes Oncology, Inflammation and Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine business units, as well as a hospital business unit; Upjohn, which includes the company's solid oral dose brands such as Lyrica, Lipitor, Norvasc, Celebrex, Viagra, and certain generic medicines; and Consumer Healthcare, which is an over-the-counter medicines business.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Rating Action: Moody's assigns A2 to Pfizer's sr. notes; stable outlook. Global Credit Research- 16 Aug 2021. New York, August 16, 2021-- Moody's Investors Service assigned an A2 rating to the new senior unsecured notes being issued by Pfizer Inc..
An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the dominant strain in most countries. We also show that recent UK studies that provided comfort regard...
The independent financial analyst theScreener just slightly lowered the general evaluation of LIFE HEALTHCARE (ZA), active in the Health Care Providers industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date September 24, 2021, the closing price was ZAR 24.15 and its potential was estimated at ZAR 28.95.
WESTAMERICA BANCORP (US), a company active in the Money Center Banks industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date September 24, 2021, the closing price was USD 55.51 and its target price was estimated at USD 48.49.
The general evaluation of WEBSTER FINANCIAL (US), a company active in the Money Center Banks industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date September 24, 2021, the closing price was USD 51.65 and its potential was estimated at USD 60.78.
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.